Seropersistence of TBE virus antibodies 10 years after first booster vaccination and response to a second booster vaccination with FSME-IMMUN 0.5mL in adults

Autor: R. Konior, J. Brzostek, L. Harper, Qin Jiang, E.M. Poellabauer, Wilhelm Erber
Rok vydání: 2016
Předmět:
Adult
Male
Pediatrics
medicine.medical_specialty
Adolescent
030231 tropical medicine
Immunization
Secondary
Enzyme-Linked Immunosorbent Assay
Disease
Antibodies
Viral
Serology
Encephalitis Viruses
Tick-Borne
03 medical and health sciences
Young Adult
0302 clinical medicine
Neutralization Tests
Seroepidemiologic Studies
Medicine
Humans
030212 general & internal medicine
Prospective Studies
Immunization Schedule
Aged
Booster (rocketry)
General Veterinary
General Immunology and Microbiology
biology
business.industry
Public Health
Environmental and Occupational Health
Viral Vaccines
Middle Aged
medicine.disease
Vaccination
Infectious Diseases
Immunology
biology.protein
Molecular Medicine
Population study
Female
Viral disease
Antibody
business
Encephalitis
Encephalitis
Tick-Borne
Follow-Up Studies
Zdroj: Vaccine. 35(28)
ISSN: 1873-2518
Popis: Tick-borne encephalitis (TBE) is a viral disease that can have a severe acute clinical course and considerable long-term morbidity. As there is no causal treatment currently available for TBE, vaccination is the only way to combat the disease in endemic areas. The studies presented here were conducted to obtain prospective long-term TBE serum antibody persistence data of subjects up to 10years after the first booster with FSME-IMMUN. This report presents the results of 2 follow-up studies in the same study population of 315 healthy adults. Blood was drawn to assess the seropersistence of TBE virus antibodies yearly, from 2-5 and 7-10years after the first booster vaccination with FSME-IMMUN administered during a previous study. The timing of the second booster vaccination was dependent on the level of serum TBE antibodies observed during yearly follow-up serology observations. The current follow up showed that adult recipients were 84.9% seropositive 10years after a 3 dose primary series and the first booster vaccination of FSME-IMMUN. Seropositivity rates were even higher (88.6%) in subjects below 50years of age. ClinicalTrials.gov Identifier: NCT00503529. ClinicalTrials.gov Identifier: NCT01582698.
Databáze: OpenAIRE
Externí odkaz: